^
Association details:
| Biomarker: | PD-L1 overexpression + RET-KIF5B fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
Published date:
03/15/2022
Excerpt:
...we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice....A 65-year-old woman...diagnosis of adenocarcinoma with 70% of PD-L1 TPS...Molecular testing confirmed CCDC6-RET fusion...pembrolizumab treatment was initiated in February 2020. Progressive disease (mediastinal lymph nodes progression, new lung nodules, bone lesions, and liver metastases) was found on CT which was performed three months later in May 2020—the patient received four doses of pembrolizumab (200 mg i.v. every 21 days) (Figure 4). Then, palliative chest radiotherapy was performed. Afterwards, due to the poor performance status...
DOI:
https://doi.org/10.3390/jcm11061630
Source:
Title:
P78.10 Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression and Coexistent RET- Fusion: The Description of Two Cases.
Published date:
01/12/2021
Excerpt:
...stage IV NSCLC adenocarcinoma -PD-L1 90%, RET-fusion KIF5B [15]-RET[12] was found. Pembrolizumab (200mg i.v. every 21 days) was initiated...CT scan revealed progressive disease (PD)within the liver and both lungs...The patient died 3 months after the diagnosis...Pembrolizumab was administered, but 3 months later PD was found...Despite the high PD-L expression (observed seldom in patients with RET abnormalities) no benefit of immunotherapy was observed in our patients.
